Shares of POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) have been given an average rating of “Hold” by the nine analysts that are covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $13.42.
Several brokerages have recently weighed in on PNT. Truist Financial lowered shares of POINT Biopharma Global from a “buy” rating to a “hold” rating and decreased their target price for the company from $13.00 to $12.50 in a research report on Tuesday, October 3rd. Raymond James downgraded shares of POINT Biopharma Global from an “outperform” rating to a “market perform” rating and cut their price target for the company from $13.00 to $12.50 in a report on Thursday, October 5th. Leerink Partnrs downgraded shares of POINT Biopharma Global from an “outperform” rating to a “market perform” rating in a report on Friday, October 6th. SVB Leerink downgraded shares of POINT Biopharma Global from an “outperform” rating to a “market perform” rating in a report on Friday, October 6th. Finally, Jonestrading reissued a “hold” rating on shares of POINT Biopharma Global in a report on Wednesday, October 4th.
Institutional Investors Weigh In On POINT Biopharma Global
POINT Biopharma Global Stock Performance
NASDAQ:PNT opened at $12.66 on Wednesday. POINT Biopharma Global has a 1 year low of $5.59 and a 1 year high of $13.02. The firm’s fifty day simple moving average is $9.67 and its 200 day simple moving average is $9.25. The company has a current ratio of 10.51, a quick ratio of 10.51 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.34 billion, a PE ratio of 14.55 and a beta of 0.22.
POINT Biopharma Global (NASDAQ:PNT – Get Free Report) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.05. The company had revenue of $4.87 million during the quarter, compared to analyst estimates of $8.50 million. On average, sell-side analysts anticipate that POINT Biopharma Global will post -1 EPS for the current year.
POINT Biopharma Global Company Profile
POINT Biopharma Global Inc, a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
- Five stocks we like better than POINT Biopharma Global
- CD Calculator: Certificate of Deposit Calculator
- Caterpillar crawls into a new buying opportunity
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- Is there merit in these low-beta moat stocks? Analysts say yes
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Oil swings have led analysts to recommend these 2 stocks
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.